Company Description
Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America.
It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.
The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems.
In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions.
It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors.
The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018.
Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
| Country | United States |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 3,771 |
| CEO | Joseph F. Woody |
Contact Details
Address: 5405 Windward Parkway, Suite 100 South Alpharetta, Georgia 30004 United States | |
| Phone | 844-428-2667 |
| Website | avanos.com |
Stock Details
| Ticker Symbol | AVNS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001606498 |
| CUSIP Number | 05350V106 |
| ISIN Number | US05350V1061 |
| Employer ID | 46-4987888 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Joseph F. Woody | Chief Executive Officer and Director |
| Michael C. Greiner | Senior Vice President, Chief Financial Officer and Chief Transformation Officer |
| Mojirade James | Senior Vice President, General Counsel and Corporate Secretary |
| Kerr W. Holbrook | Senior Vice President and Chief Commercial Officer |
| John Joseph Hurley | Principal Accounting Officer and Controller |
| David Crawford | Vice President of FP&A and Investor Relations and Treasurer |
| Michelle Scharfenberg | Senior Vice President and Chief Ethics and Compliance Officer |
| Scott Galovan | Vice President of Strategy and Corporate Development |
| John W. Cato | Vice President of Human Resources |
| Lee Burnes | Senior Vice President of Global Research & Development, Clinical and Medical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 18, 2024 | ARS | Filing |
| Mar 15, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 15, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 14, 2024 | 144 | Filing |
| Feb 21, 2024 | 10-K | Annual Report |
| Feb 20, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |